Key facts
- This page summarizes Jared Watkin's Form 4 filing for ABBOTT LABORATORIES (ABT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 02 Mar 2023, 18:59.
Jared Watkin - 28 Feb 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)
- Reporting relationship
- SENIOR VICE PRESIDENT
- Issuer ticker
- ABT
- Reported as of
- 28 Feb 2023
- Net transaction value
- -$679,151
- SEC form
- 4
- Accepted by SEC
- 02 Mar 2023, 18:59:16 UTC
- Prior SEC filing
- 22 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jared Watkin by Jessica H. Paik, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jared Watkin filed Form 4 for ABBOTT LABORATORIES (ABT) on 02 Mar 2023.
Change
- Previous filing in this sequence was filed on 22 Feb 2023.
- Current net transaction value: -$679,151.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABT
transaction
Common shares without par value
Tax liability
- Transaction value
- $558,512
- Shares
- -5,598
- Change %
- -7.2%
- Price
- $99.77
- Shares after
- 72,564
- Date
- 28 Feb 2023
- Ownership
- Direct
ABT
transaction
Common shares without par value
Sale
- Transaction value
- $120,639
- Shares
- -1,198
- Change %
- -1.7%
- Price
- $100.70
- Shares after
- 71,366
- Date
- 01 Mar 2023
- Ownership
- Direct
ABT
holding
Common shares without par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 652
- Date
- 28 Feb 2023
- Ownership
- Profit Sharing Trust
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023.
SEC remarks
The sale transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1(c).